RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Daviddal, One area where I thought Cortex had potentially dropped the ball bigtime was in the design of the ADHD trial (only two doses, each at the most extreme ends of the dosing range with nothing in the middle). Luckily everything worked out in the end, but if that super high 800 mg BID dose had caused a lot of dropouts, which was a distinct possibility, then the trial results would have been pretty worthless in assessing CX-717's potential for ADHD. Luckily things worked out, but to me it still seemed like a needlessly risky protocol.

The poor DARPA protocol was something Cortex really had no control over. The poor AD PET scan trial protocol was caused by the sudden emergence of the Aricept/Namenda combo approach, and the lack of previous data on CX-717 for that combo regimen. Cortex can probably be excused for that misstep, though perhaps starting a 2nd different type AD trial earlier could have been done (as they're doing now).

Of course it all gets back to a lack of resources/cash, which is the underlying basis for most of Cortex's troubles (the thin pipeline / over-reliance on CX-717 / lack of progress on the high impacts, etc). They say that the love of money is the root of all evil, but in biotech, it's the lack of money.